Home › Bristol-Myers Squibb To Acquire Padlock Therapeutics, Inc.
 

Keywords :   


Bristol-Myers Squibb To Acquire Padlock Therapeutics, Inc.

2016-03-30 03:53:43| drugdiscoveryonline Home Page

Bristol-Myers Squibb Company and Padlock Therapeutics, Inc. announced recently that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of Padlock, a private, Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases

Tags: acquire therapeutics squibb padlock

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05Panasonic offers Fire TV, Google TV and Powered by TiVo
20.05Eutelsat reports results for the period ended 31 March 2024
20.05WCC Re-elects Tom Bowtell for Second Term as President, Recognizes Contributions of Andy Doyle
20.05May/June 2024 Digital Edition of National Hog Farmer now available
20.05DKSH Extends Distribution Agreement with KRONOS in Asia Pacific
20.05Valmet Names New Vice President Services, North America
20.05NABC hosts foreign animal disease tabletop exercise
20.05NABC hosts foreign animal disease tabletop exercise
More »